Mylan saw EpiPen pricing trouble coming months ago. So the company stepped up lobbying for EpiPen's move onto an official list of preventive meds that…

The EpiPen drama is moving into a congressional hearing room. Mylan CEO Heather Bresch is on the docket to testify next Wednesday for the House Committee on…

Pfizer’s stop-smoking drug Chantix may be one step closer to escaping the FDA’s black box. An agency advisory panel narrowly voted in favor of removing the FDA…

Not atypically, the FDA questioned Pfizer’s Chantix data up for discussion at a meeting Wednesday. But agency reviewers also raised an unusual flag: Pfizer…

Generic drug prices in Medicare Part D decreased significantly in recent years. So why the worry about price hikes? "Extraordinary" increases on…

FDA scientists are looking askance at Pfizer’s latest attempt to lift a black-box warning from its stop-smoking drug Chantix.

Pfizer CEO Ian Read called Hillary Clinton's plan to curb drug prices "very negative for innovation."

Biogen rolled out its Remicade biosimilar in the U.K., thus becoming the first drugmaker to market two anti-TNF biosims there. But don't expect anyone to…